ArticleJournal of the American Heart Association2022
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial.
Article in Journal of the American Heart Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease
Impact of Combined cARdio-pUlmonary aSsessment on COPD Clinical Management: the ICARUS Study
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Impact of positive airway pressure for chronic hypercapnic respiratory failure on sleep quality: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2025Pooled it
- A 7-point evidence-based care discharge protocol for patients hospitalized for exacerbation of COPD: consensus strategy and expert recommendation.NPJ primary care respiratory medicine · 2024Pooled it
- Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2023Pooled it
- ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD.The European respiratory journal · 2025Trial
- Patterns of Comorbidity in Asthma-COPD Overlap Cohort According to Various ACO Definitions.Advances in respiratory medicine · 2026Article
- Acute exacerbation of chronic obstructive pulmonary disease as a short-term cardiopulmonary risk window: a time-stratified systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Article
- Challenges in the Early Diagnosis, Screening and Management of Heart Failure in Patients with Chronic Obstructive Pulmonary Disease.Journal of clinical medicine · 2026Review
- Long-term cardiovascular risk after severe exacerbation of COPD: a population-based cohort study.ERJ open research · 2026Article
- Third Year in Review, Fourth Year in Preview, and the 2025Journal of the American Heart Association · 2026Article
- Temporal trends in stroke-prevention medication use in patients with atrial fibrillation and chronic obstructive pulmonary disease.Frontiers in pharmacology · 2026Article
- Prevalence of Chronic Obstructive Pulmonary Disease and Asthma in Polycythemia Vera and Essential Thrombocythemia and Its Prognostic Implications.Journal of clinical medicine · 2025Article
- Cardiopulmonary risk in the COPD patient: the EPOCONSUL audit.Scientific reports · 2025Article
- Healthcare resource utilisation in patients with exacerbations of COPD and associated cardiovascular events: the EXACOS-CV study.ERJ open research · 2025Article
- The sustained increase of cardiovascular risk following COPD exacerbations: meta-analyses of the EXACOS-CV studies.ERJ open research · 2025Article
- Using machine learning to predict deterioration of symptoms in COPD patients within a telemonitoring program.Scientific reports · 2025Article
- Risk of Atherosclerotic Cardiovascular Disease After Chronic Obstructive Pulmonary Disease Hospitalization among Primary and Secondary Prevention Older Adults.Journal of the American Heart Association · 2025Article
- GEVResearch (Washington, D.C.) · 2025Article
- Diagnosis and management of comorbid disease in COPD.Breathe (Sheffield, England) · 2025Review
- Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 12 institutions in 3 countries.
Funding
Abstract
Background The association between chronic obstructive pulmonary disease exacerbations and increased cardiovascular event risk has not been adequately studied in a heterogenous population with both low and high cardiovascular risk. Methods and Results This post hoc analysis of the IMPACT (Informing the Pathway of COPD Treatment) trial (N=10 355 symptomatic patients with chronic obstructive pulmonary disease at risk of exacerbations) evaluated time-dependent risk of cardiovascular adverse events of special interest (CVAESI) following exacerbations and impact of exacerbation history, cardiovascular risk factors, and study treatment on this association. Risk (time-to-first) of CVAESI or CVAESI resulting in hospitalization or death was assessed during and 1 to 30, 31 to 90, and 91 to 365 days after resolution of moderate or severe exacerbations. CVAESI risk was compared between the period before and during/after exacerbation. CVAESI risk increased significantly during a moderate (hazard ratio [HR], 2.63 [95% CI, 2.08-3.32]) or severe (HR, 21.84 [95% CI, 17.71-26.93]) exacerbation and remained elevated for 30 days following an exacerbation (moderate: HR, 1.63 [95% CI, 1.28-2.08]; severe: HR, 1.75 [95% CI, 0.99-3.11; nonsignificant]) and decreased over time, returning to baseline by 90 days. Risk of CVAESI resulting in hospitalization or death also increased during an exacerbation (moderate: HR, 2.46 [95% CI, 1.53-3.97]; severe: HR, 41.29 [95% CI, 30.43-56.03]) and decreased in a similar time-dependent pattern. Results were consistent regardless of exacerbation history, cardiovascular risk at screening, or study treatment. Conclusions Overall risk of cardiovascular events was higher during and in the 30 days following chronic obstructive pulmonary disease exacerbations, even among those with low cardiovascular risk, highlighting the need for exacerbation prevention and vigilance for cardiovascular events following exacerbations. Registration URL: https://clinicaltrials.gov/ct2/show/NCT02164513; Unique identifier: NCT02164513.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.